E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 7/29/2005 in the Prospect News Biotech Daily.

Dynavax kept by JMP at market outperform

Dynavax Technologies Corp. was reiterated by JMP Securities analyst Charles Duncan at a market outperform rating with a price target on the stock of $9 per share following second-quarter results. Dynavax shares Friday were down $0.12, or 2.21%, at $5.30 on volume of 9,000 shares versus the three-month running average of 36,886.2 shares.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.